Association between COVID-19 and angiotensin-converting enzyme inhibitors with the spotlight on zinc: an opinion.
Ann Med
; 53(1): 1673-1675, 2021 12.
Article
in English
| MEDLINE | ID: covidwho-1437738
ABSTRACT
In the setting of the raging COVID-19 pandemic, the search for innovative therapeutics is desperately sought after. As we learn more about the characteristics and metabolic health of patients and as our understanding of COVID-19 pathophysiology and treatment progresses, so is our understanding of medication effects that might increase disease severity. As of late, ACE inhibitors have been under investigation for a potential increase in illness severity due to ACE2 upregulation. Given our knowledge of other nutrient-pharmaceutical interactions, could the ACE inhibitor impact on COVID be due to something else? In this paper, we discuss the possibility that ACE inhibitors might be affecting COVID-19 patients by causing zinc insufficiency.KEY MESSAGESZinc deficiency caused by chronic ACE inhibitor usage may exacerbate the pathogenicity of COVID-19 in susceptible patients.A multi-center study is needed to assess the zinc levels of patients with COVID-19 who are taking ACE inhibitors and other medications that may result in low zinc levels.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Zinc
/
Angiotensin-Converting Enzyme Inhibitors
/
Angiotensin-Converting Enzyme 2
/
COVID-19 Drug Treatment
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Ann Med
Journal subject:
Medicine
Year:
2021
Document Type:
Article
Affiliation country:
07853890.2021.1981545
Similar
MEDLINE
...
LILACS
LIS